Ticker brief

PODD INSULET CORP

Consumer, Non-cyclical · Healthcare-Products

last close
$164.48
1 day
+2.9%
14 days
+12.8%
mkt cap
$11.4B
signals 14d
20
authors 14d
10
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-07-02 · now -0.25 (−1 bearish … +1 bullish)
Who spoke10
authorgradetrader scoresignalsmean sent
@FluentInQualityB+0.968+0.56
@VistaPResearchC·4+0.14
@MacroAlphaHQA+1.151-0.75
@MinnvestorA-1.191+0.25
@CEOStockWatcherC·1+0.25
@BlueJay87476298B+1.051+0.35
@ClassicRoyC+2.011+0.25
@VladBastionB+1.881+0.20
@OracleNYSEC+0.491-0.40
@PeloSwingC-1.441-0.40
Recent signals20of 20 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-07-02@PeloSwing-0.40Reports FDA Class I recall for PODD Omnipods, despite stock reaction higher.
2026-07-02@OracleNYSE-0.40FDA updated PODD issue as Class I recall, the most serious type.
2026-07-02@VistaPResearch+0.05Article title pitches Modular Medical's pivot and easier diabetes care.
2026-07-01@VladBastion+0.20Detailed PODD thesis: recall hurt trust but guidance unchanged and quality score remains high.+2.9%
2026-06-30@VistaPResearch+0.25Article title about Modular's Pivot and Insulet's Omnipod rewriting diabetes playbook.+8.0%
2026-06-30@ClassicRoy+0.25Reports options volume surge multiples for top momentum names.+8.0%
2026-06-29@VistaPResearch+0.25Article title about Modular's Pivot and Insulet's Omnipod rewriting diabetes playbook.+4.3%
2026-06-29@BlueJay87476298+0.35Goldman-style medtech note lists Buy ratings for ABT/BBNX/DXCM/PODD/MMED and Neutral TNDM.+4.3%
2026-06-29@CEOStockWatcher+0.25Reply says PODD may be most interesting due to less exposure to regulation/reimbursement.+4.3%
2026-06-26@VistaPResearch+0.00Modular Medical announces shipment of Pivot tubeless patch pumps.+3.9%
2026-06-24@FluentInQuality+0.55Bullish on PODD pharmacy distribution, coverage and injection user switching.+10.5%
2026-06-24@FluentInQuality+0.70Frames PODD as recurring-revenue machine growing 30% with $12B Type 2 market opening.+10.5%
2026-06-24@FluentInQuality+0.35Describes PODD Omnipod tubeless patch that delivers insulin automatically.+10.5%
2026-06-24@FluentInQuality+0.50Explains Omnipod consumable replacement model and lifelong pod demand.+10.5%
2026-06-24@FluentInQuality+0.70Bullish on PODD Type 2 diabetes AID penetration and $12B+ market opportunity.+10.5%
2026-06-24@FluentInQuality+0.55Describes PODD recurring revenue razor-and-blade model from disposable pods.+10.5%
2026-06-24@FluentInQuality+0.55Lists PODD margins, operating margin expansion and free cash flow.+10.5%
2026-06-24@FluentInQuality+0.60Says PODD achieved ten straight years of 20%+ revenue growth.+10.5%
2026-06-23@Minnvestor+0.25Lists lowest forward PEG ratios among >3% gainers with >20% 3Y sales CAGR.+14.3%
2026-06-19@MacroAlphaHQ-0.75Bearish on PODD despite Strong Buy and FDA-clearance headlines, framing PTs as exit liquidity.+12.8%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.